Biomarkers of Atrial Fibrillation: Which One Is a True Marker?

Abstract EN

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmias and associated with the risk of stroke and death.

Continuous development of the diagnostic tool and prognostic stratification may lead to optimal management of AF.

The use of biomarkers in the management of AF has been grown as an interesting topic.

However, the AF biomarkers are not yet well established in the major guidelines.

Among these biomarkers, a lot of data show troponin and brain natriuretic peptides are promising for the prediction of future events.

The troponin elevation in AF patients may not necessarily be diagnosed as myocardial infarction or significant coronary artery stenosis, and brain natriuretic peptide elevation may not necessarily confirm heart failure.

Troponin T and troponin I may predict postoperative AF.

Furthermore, troponin and brain natriuretic peptide gave better prognostic performance when compared with the risk score available today.